RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients

Luo, Yihuan; Liang, Liang; He, Rong‐Quan; Wen, Dong‐Yue; Deng, Guofei; Yang, Hong; He, Yun; Ma, Wei; Cai, Xiujun; Chen, Junqiang; Chen, Gang

doi:10.18632/oncotarget.18274

Cited by 29 publications

(28 citation statements)

References 45 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that the expression level of lncRNA PAX8-AS1:28 is commonly decreased in patients with neck squamous cell carcinoma, and a higher expression level of lncRNA PAX8-AS1:28 is closely correlated with better survival outcome (18). lncRNA PAX8-AS1:28 expression is also downregulated in patients with PTC (11), and the reduced expression level of lncRNA PAX8-AS1:28 is closely correlated with the poor survival of these patients (19). Consistent with previous studies, in our study, the expression level of PAX8-AS1:28 was found to be lower in PTC tissues and PTC cells than that in adjacent healthy tissues and a normal cell line.…”

Section: Discussionsupporting

confidence: 91%

MYC promotes the development of papillary thyroid carcinoma by inhibiting the expression of lncRNA PAX8‑AS1:28

Zhang

2019

Oncol Rep

View full text Add to dashboard Cite

As a common malignancy of the endocrine system, papillary thyroid carcinoma (PTC) seriously affects the quality of life of patients. lncRNA PAX8-AS1:28, or lnc-PSD4-1:14 has been reported to be abnormally expressed in PTC. However, the function of PAX8-AS1:28 in PTC is still unknown. Therefore, the present study aimed to investigate the functions of PAX8-AS1:28 in PTC, and to explore the possible mechanisms of action. A total of 38 patients with PTC were included and the normal thyroid follicular epithelial cell line Nthy-ori 3-1 and PTC cell line IHH-4 were also used. MYC and PAX8-AS1:28 overexpression and siRNA silencing in the cell lines were carried out. Expression of PAX8-AS1:28, PAX8 and MYC in tumor tissue, adjacent healthy tissue and different cell lines were detected by qRT-PCR and western blot analysis. Cell proliferation was measured by CCK-8 assay. Expression levels of PAX8-AS1:28 and PAX8 were lower in PTC tumor tissue and PTC cells than those in healthy tissue and normal cells. In contrast, the expression level of MYC was higher in PTC cells than that in normal cells. PAX8-AS1:28 silencing reduced the expression level of PAX8 and promoted tumor cell growth, while PAX8-AS1:28 overexpression increased the expression level of PAX8 and inhibited tumor cell growth. MYC silencing increased expression levels of PAX8-AS1:28 and PAX8 and inhibited tumor cell growth, while MYC overexpression decreased expression levels of PAX8-AS1:28 and PAX8 and promoted tumor cell growth. MYC can promote PTC by inhibiting the expression of lncRNA PAX8-AS1:28.

show abstract

Section: Discussionsupporting

confidence: 91%

MYC promotes the development of papillary thyroid carcinoma by inhibiting the expression of lncRNA PAX8‑AS1:28

Zhang

2019

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Unfortunately, no survival information of PTC lncRNA was available in the datasets. 37 Therefore, the candidate lncRNAs in the risk sore model were different in our studies, and the three-lncRNA prognostic signature was credible to be a potential biomarker.…”

Section: Discussionmentioning

confidence: 66%

“…Han et al 36 mined the data in the TCGA database, and then 19 significant gene pairs with high diagnostic ability were detected. Luo et al 37 identified a three-lncRNA signature (AC079630.2, CRNDE and CTD-2171N6.1) to predict the PTC patients’ survival. Li et al 38 also provided a four-lncRNA signature (RP11-536N17.1, RP11-508M8.1, AC026150.8 and CTD-2139B15.2) to improve the prognosis prediction of PTC patients.…”

Section: Discussionmentioning

confidence: 99%

Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature

You¹,

Yang²,

Sui³

et al. 2018

CMAR

View full text Add to dashboard Cite

PurposePapillary thyroid carcinoma (PTC), the most frequent type of malignant thyroid tumor, lacks novel and reliable biomarkers of patients’ prognosis. In the current study, we mined The Cancer Genome Atlas (TCGA) to develop lncRNA signature of PTC.Patients and methodsThe intersection of PTC lncRNAs was obtained from the TCGA database using integrative computational method. By the univariate and multivariate Cox analysis, key lncRNAs were identified to construct the prognostic model. Then, all patients were divided into the high-risk group and low-risk group to perform the Kaplan–Meier (K–M) survival curves and time-dependent receiver operating characteristic (ROC) curve, estimating the prognostic power of the prognostic model. Functional enrichment analysis was also performed. Finally, we verified the results of the TCGA analysis by the Gene Expression Omnibus (GEO) databases and quantitative real-time PCR (qRT-PCR).ResultsAfter the comprehensive analysis, a three-lncRNA signature (PRSS3P2, KRTAP5-AS1 and PWAR5) was obtained. Interestingly, patients with low-risk scores tended to gain obviously longer survival time, and the area under the time-dependent ROC curve was 0.739. Furthermore, gene ontology (GO) and pathway analysis revealed the tumorigenic and prognostic function of the three lncRNAs. We also found three potential transcription factors to help understand the mechanisms of the PTC-specific lncRNAs. Finally, the GEO databases and qRT-PCR validation were consistent with our TCGA bioinformatics results.ConclusionWe built a three-lncRNA signature by mining the TCGA database, which could effectively predict the prognosis of PTC.

show abstract

“…[3][4][5][6] With appropriate treatments such as operation and radioactive iodine ablation, the majority of PTCs have excellent prognoses with an overall survival rate of 97.7% at 5 years. 7,8 Nonetheless, up to 20% patients can suffer locoregional recurrence, and occasionally some progress to aggressive and lethal outcomes. 9 Molecular mechanisms contributing to its carcinogenesis and progression remain obscure.…”

Section: Introductionmentioning

confidence: 99%

<p>Correlations of lncRNAs with cervical lymph node metastasis and prognosis of papillary thyroid carcinoma</p>

Cui

et al. 2019

OTT

View full text Add to dashboard Cite

Background Cervical lymph node metastasis is an important prognostic indicator for papillary thyroid carcinoma (PTC) and affects treatment strategies for PTC. lncRNAs essentially contribute to the biological functions of tumors. This study aimed to identify the lncRNAs associated with cervical lymph node metastasis and prognosis of PTC and their potential pathophysiological mechanisms. Materials and methods PTC-associated lncRNAs were selected from The Cancer Genome Atlas database, and correlations among lncRNAs, lymph node metastasis, tumor staging, and prognosis of PTC were analyzed in silico. These correlations were then validated through quantitative reverse transcription PCR (qRT-PCR) and immunohistochemistry (IHC). Results In silico analysis showed that FAM95B1 and UCA1 were significantly correlated with cervical lymph node metastasis, tumor staging, and PTC prognosis ( P <0.05). qRT-PCR analysis revealed high UCA1 expression in PTC tissues and correlations between UCA1 expression levels and cervical lymph node metastasis and tumor staging in PTC, that is, higher UCA1 expression resulted in poorer PTC prognosis. IHC analysis revealed that a high expression of UCA1 was accompanied by a high expression of metastasis-related proteins (MMP-2 and MMP-9), thereby validating the correlation of UCA1 expression with metastasis. Conclusion FAM95B1 and UCA1 expression was significantly correlated with the occurrence and progression of PTC. The expression levels of UCA1 significantly affected the prognosis of PTC patients and were significantly correlated with tumor staging and cervical lymph node metastasis.

show abstract

RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients

Cited by 29 publications

References 45 publications

MYC promotes the development of papillary thyroid carcinoma by inhibiting the expression of lncRNA PAX8‑AS1:28

MYC promotes the development of papillary thyroid carcinoma by inhibiting the expression of lncRNA PAX8‑AS1:28

Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature

<p>Correlations of lncRNAs with cervical lymph node metastasis and prognosis of papillary thyroid carcinoma</p>

Contact Info

Product

Resources

About